Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

363
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
363

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same author

Bronchiolitis Post Introduction of RSV Immunoprophylaxis: Shifting Patterns in Pediatric Hospitalizations.

Clinical pediatrics·2026
Same author

A negative-hydrated constriction zone is revealed in the active state of the H<sub>v</sub>1 channel.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Direct targeting of C9ORF72 repeat RNA with fluorinated antisense oligonucleotides.

Nucleic acids research·2026
Same author

What I talk about when I talk about patient self-inflicted lung injury: an ultrastructural perspective.

Intensive care medicine experimental·2026

相关实验视频

Updated: Jun 29, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

固体瘤的采用T细胞疗法:当前的景观和未来的挑战.

Víctor Albarrán1, María San Román1, Javier Pozas2

  • 1Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain.

Frontiers in immunology
|March 29, 2024
PubMed
概括

采用细胞疗法 (ACT) 对固体瘤具有前景,瘤透淋巴细胞 (TIL) 疗法成为关键策略. 挑战仍然存在,但研究正在推进耐火性癌症的T细胞疗法.

关键词:
在T细胞,T细胞.用TCR修饰的细胞.在TIL治疗中,治疗方法是TIL.采用细胞疗法采用细胞疗法汽车-t-t 在车上免疫疗法 免疫疗法黑色素瘤是一种黑色素瘤.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

893

相关实验视频

Last Updated: Jun 29, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

893

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 细胞疗法细胞疗法

背景情况:

  • 采用细胞疗法 (ACT) 增强了对抗瘤的T细胞活性.
  • 化学抗原受体 (CAR) T细胞疗法在血液癌症中取得了成功.
  • 固体瘤对ACT来说具有异质性和免疫抑制等挑战.

研究的目的:

  • 审查关于固体瘤T细胞治疗的当前知识.
  • 总结实体瘤中ACT模式的临床结果.
  • 确定T细胞治疗在瘤学的未来研究方向.

主要方法:

  • 对实体瘤的ACT现有文献的综述.
  • 对CAR T细胞,TCR工程T细胞和TIL治疗的临床结果的分析.
  • 讨论T细胞治疗的挑战和未来前景.

主要成果:

  • 由于瘤特征,CAR T细胞在固体瘤中面临有效性限制.
  • 瘤透性淋巴细胞 (TIL) 疗法在某些癌症,如黑色素瘤中表现有前途.
  • 将TIL治疗与免疫检查点抑制剂相结合是一种潜在的策略.

结论:

  • 尽管存在实施方面的挑战,但TIL疗法对于固体瘤是一种有前途的ACT疗法.
  • 需要进一步的研究来克服生物,后勤和经济障碍,以便广泛使用TIL疗法.
  • 治疗T细胞治疗具有治疗耐火实体瘤患者的巨大潜力.